A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
To avoid the deep disagreements surrounding the theories of the essential features of well-being, some researchers examine components and contributing factors, independent of whether they are integral parts or external causes. For example, there is wide agreement that positive emotions, achievements, interpersonal relationships, and health typically contribute to well-being in some form, despite academic disagreement about their precise roles.
== Professional ventures and affiliations == Early in his career, Ariely co-founded the behavioral economics consulting firm BEworks, which was acquired by Kyu in 2017. In 2012, aspiring to develop a time management app that helps people "use time better" and avoid procrastination, Ariely co-founded Timeful with Yoav Shoham and Jacob Bank. The app was acquired by Google in 2015. In 2013, Ariely and Kristen Berman co-founded Irrational Labs, a consulting firm aimed at applying behavioral economics to consumer behavior and decision-making. In 2014, Ariely co-founded the kitchen appliance company Genie with Ayelet Carasso-Stenberg and Doron Marco. Genie manufactures a food "replicator" that cooks freeze-dried meals in cartridges. In 2015, Ariely invested in Qapital, a personal finance app, and was appointed as its chief behavioral economist. He was later named chair of the board. In 2015, Ariely gave a talk at Google about dating and relationships, discussing what women want from men, including how women's attraction to men varies depending where they are in their menstrual cycle. This was one of many talks Ariely collaborated with Google on over several years, including, for example, a talk about how people rationalize cheating. In 2016, he took on the position of chief behavioral officer at Lemonade, an insurance company that integrates aspects of behavioral economics into its insurance model. Ariely's entrepreneurial ventures also include founding Shapa in 2017, a company focused on health monitoring and behavior change.
Spelt has been cultivated since approximately 5000 BCE. In the fifth millennium BCE, there are archaeological remains in the north of Iraq and in Transcaucasia, north-east of the Black Sea. Much more evidence comes from Europe. Remains of spelt have been found in Denmark, Germany, and Poland from the later Neolithic (dating from 2500–1700 BCE). Evidence of spelt has been found from across central Europe from the Bronze Age. In the south of Germany and Switzerland in the Iron Age (750–15 BCE), it was a major type of wheat, while by 500 BCE, it had in addition become widespread in the south of Britain. There is evidence that spelt cultivation increased in Iron Age Britain as damp regions of the country with heavy soils tolerated by spelt were being settled. In the Middle Ages, spelt was cultivated in parts of Switzerland, Tyrol, Germany, northern France and the southern Low Countries. Spelt became a major crop in Europe in the 9th century CE, possibly because it is more suitable for storage and being husked makes it more adaptable to cold climates. Spelt was introduced to the United States in the 1890s. In the 20th century, spelt was replaced by bread wheat in almost all areas where it was still grown. The organic farming movement revived its popularity somewhat toward the end of the 20th century, as spelt requires less fertilizer. Since the beginning of the 21st century, spelt has become a common wheat substitute for making artisanal loaves of bread, pasta, and flakes. By 2014, the grain was popular in the UK, Kazakhstan, and Ukraine.
=== As a drug target === Because of their tissue selectivity and persistent expression recombinant adeno-associated viruses (AAV) have therapeutic potential in the treatment of inherited cardiomyopathy resulting from MYBPC3 mutations- Several targeting approaches have been developed. The most recent is genome editing to correct a mutation by CRISPR/Cas9 technology. Naturally existing as part of the prokaryotic immune system, the CRISPR/Cas9 system has been used for correction of mutations in the mammalian genome. By inducing nicks in the double-stranded DNA and providing a template DNA sequence, it is possible to repair mutations by homologous recombination. This approach has not yet been evaluated for MYBPC3 mutations, but it could be used for each single or clustered mutation, and therefore applied preferentially for frequent founder MYBPC3 mutations. Other strategies targeting the mutant pre-mRNA by exon skipping and/or spliceosome-mediated RNA trans-splicing (SMaRT) have been evaluated for MYBPC3. Exon skipping can be achieved using antisense oligonucleotide (AON) masking exonic splicing enhancer sequences and therefore preventing binding of the splicing machinery and therefore resulting in exclusion of the exon from the mRNA. This approach can be applied when the resulting shorter, but in-frame translated protein maintains its function. Proof-of-concept of exon skipping was recently shown in homozygous Mybpc3-targeted knock-in mice.
chemical substance Also pure substance or simply substance. A form of matter that has constant chemical composition and characteristic properties and which cannot be separated into simpler components by purely physical methods (i.e. without breaking chemical bonds). It is often called a pure substance to distinguish it from a mixture.
Sources: en.wikipedia.org
For services to Further Education and Skills Michael Davidson. Volunteer and Trustee, Royal Ulster Constabulary George Cross Foundation. For Voluntary Service. Janet Ann Davies. Councillor, Denbighshire County Council. For services to Local Government, to the NHS and to the community in Rhuddlan, Denbighshire. Jean Carol Davies. Chair and Coach, Saints Netball Club, Truro. For services to Netball and to the community in Cornwall. Dr Robert Havard Davies. Doctor, Neuro-Development Team, Betsi Cadwaladr University Health Board. For services to the NHS. Francisco Domingo Davila Davila. For services to the community in Wymondham, Norfolk. Brendan William Davis. Head of Operations, Government Car Service. For services to Government and Major Events. Rachel Frances Davis. For services to the community in Cranford, Northamptonshire. Audrey Dempsey. Founder, Glasgow's No1 Baby and Family Support Service. For services to Families and Vulnerable People in Glasgow. Janet Mary Dicks. For services to the community in Hadleigh, Suffolk. Ann Doreen May Doody. For services to the community in Ilfracombe, Devon. Trevor Samuel John Douglas. General Manager, Belfast Cathedral. For services to Peacebuilding and to the community in Northern Ireland. Lee William Doyle. Chief Executive Officer, Brentford FC Community Sports Trust. For services to Sport and to the community in Brentford, London Borough of Hounslow. Janet Shirley Dyer. Catering Manager, National Fire Service College. For services to the community in Moreton-in-Marsh, Gloucestershire. Patricia Carol Earl.
== ADLM Annual Scientific Meeting == ADLM holds several scientific conferences each year, the largest of which is the ADLM Annual Scientific Meeting & Clinical Lab Expo. First held in 1949, this educational meeting and technology exposition is an event in the field of laboratory medicine, attracting an average of 20,000 participants.
== Side effects == Adverse effects of hydromorphone are similar to those of other potent opioid analgesics such as morphine and heroin. The major hazards of hydromorphone include dose-related respiratory depression, urinary retention, bronchospasm, and sometimes, circulatory depression. More common side effects include lightheadedness, dizziness, nystagmus, sedation, itching, constipation, nausea, vomiting, headache, perspiration, and hallucinations. These symptoms are common in ambulatory patients and in those not experiencing severe pain. Simultaneous use of hydromorphone with other opioids, muscle relaxants, tranquilizers, sedatives, and general anesthetics may significantly depress respiration, progressing to coma or death. Taking benzodiazepines (e.g., diazepam) in conjunction with hydromorphone may increase side effects such as dizziness and difficulty concentrating. If simultaneous use of these drugs is required, dose adjustment may be made. A particular problem that may occur with hydromorphone is accidental administration in place of morphine due to a mix-up between the similar names, either at the time the prescription is written or when the drug is dispensed. This has led to several deaths and calls for hydromorphone to be distributed in distinctly different packaging from morphine to avoid confusion. Massive overdoses are rarely observed in opioid-tolerant individuals, but when they occur, they may lead to circulatory system collapse.
=== Patent litigation === In May 2009, Johnson & Johnson's Centocor unit, the maker of infliximab, won a ruling for $1.67 billion from Abbott Laboratories for patent infringement on the process for making Humira. However, in 2011, the judgment was overturned by the United States Court of Appeals for the Federal Circuit. In June 2020, a class action lawsuit filed by United Food and Commercial Workers Local 1500 (UFCW Local 1500) against AbbVie, alleging that the drug manufacturer used a patent thicket over 100 strong to maintain a monopoly on Adalimumab, was dismissed by the Northern District Court in Illinois. The dismissal was affirmed by the Seventh Circuit Court of Appeals on 1 August 2022. AbbVie has extensively used the US patent system to delay competitors from entering the market, a process commonly known as "evergreening". It filed 311 patents for Humira, of which 165 were granted. AbbVie sued Amgen, the manufacturer of Amjevita, in 2016 for violating 10 of its patents. Amgen agreed to delay sales until 2023, which allowed AbbVie to drive up prices of Humira. Between 2016 and 2023, the price of Humira went up by 60%, during which time AbbVie made $114 billion in revenue from Humira.
=== Industrial production of chemicals === The dominant use for sulfuric acid is in the "wet method" for the production of phosphoric acid, used for manufacture of phosphate fertilizers. In this method, phosphate rock is used, and more than 100 million tonnes are processed annually. This raw material is shown below as fluorapatite, though the exact composition may vary. This is treated with 93% sulfuric acid to produce calcium sulfate, hydrogen fluoride (HF) and phosphoric acid. The HF is removed as hydrofluoric acid. The overall process can be represented as:
Sources: en.wikipedia.org
"[...] we commend the Anti-Eugenics Project for their essential work to understand[...] the harmful legacies of eugenicist ideologies. [...] examine the role that philanthropies played in developing and perpetuating eugenics policies and practices. The Rockefeller Foundation is currently reckoning with our own history in relation to eugenics. This requires uncovering the facts and confronting uncomfortable truths, [...] The Rockefeller Foundation is putting equity and inclusion at the center of all our work: [...] confronting the hateful legacies of the past [...] we understand that the work we engage in today does not absolve us of yesterday's mistakes. [...]"
mobilome The complete set of mobile genetic elements within a particular genome, cell, species, or other taxon, including all transposons, plasmids, prophages, and other self-splicing nucleic acid molecules.
=== Ritual Magic === During the Renaissance in Iceland, blotting paper had a small religious significance as a tool for ceremonial magic. This becomes noticeable in the Galdrabók, a grimoire (magic spell book) of the period, in which the reader is directed to draw sigils on blotting paper to attain success.
Two people were killed by Russian shelling in Ukrainsk, Donetsk Oblast. One person was killed in a separate attack in Komar. Russia launched an air attack on Myrhorod Air Base in Poltava Oblast. The Ukrainian Air Force acknowledged damage, with two of the base's six Su-27s destroyed by an Iskander missile with a cluster warhead. A drone attack was reported in Sevastopol and other parts of Crimea, with the Ukrainian Air Force later claiming to have struck an ammunition dump using six Storm Shadow cruise missiles. The ammunition dump was also believed to host a "Shahed drone warehouse". Russian sources claimed that five aerial targets were shot down. Ukrainian drone attacks left parts of Belgorod Oblast without power. Ukrainian media reported that a drone strike the Oskol Electrometallurgical Plant, Russia's only full-cycle metallurgical enterprise, in Stary Oskol. Scouts from the Ukrainian Rubizh Brigade captured "several dozen Russian soldiers", mostly mobilised conscripts, in an unspecified location. Dutch defence minister Kajsa Ollongren announced that the export permits allowing the export of 24 F-16s to Ukraine had been granted, with their arrival set on a "confidential" date. The SBU claimed to have foiled a coup by a Russian-backed group against the Ukrainian government that was scheduled on 30 July. Russia claimed to have captured an ATACMS missile guidance system intact and was studying it to "identify any weak spots".
The report that CMS requires labs to prominently display complaint posters instructing lab workers how to file anonymous complaints. In a July 2007 response to the GAO, CMS said that it lacked the legal authority to mandate labs to display posters. They plan to take several other steps to increase awareness of complaint processes including: (1) posting fact sheet on the CMS web site on complaint filing (2) adding information on filing complaints to the interpretive guidelines used by surveyors (3) adding complaints received by accrediting organizations to their complaints database and (4) reminding states and accrediting organizations by letter about the importance of complaints. CMS reported that it sent a letter about complaint tracking to accreditation organizations, exempt states, and professional laboratory organizations on November 30, 2007. According to CMS, this letter highlighted the importance of complaint tracking and filing, and encouraged the publication of compliant processes. CMS has also developed a CLIA Brochure on Complaints, which was being prepared for release as of September 2008. Once released, CMS anticipates posting the brochure on its website and printing copies for distribution to laboratories. We will continue to monitor the implementation of this recommendation. In 2009, the GAO recommended that CMS require all survey organizations to develop and require labs to prominently display posters instructing lab workers how to file anonymous complaints.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.